Aurobindo Pharma Ltd.

NSE: AUROPHARMA · Healthcare

₹1,800.00+0.84%06 Nov 2026

Ask the data

Instant answers about Aurobindo Pharma Ltd. — computed from its filings, no language model

Market cap₹1,03,572 cr

Current price₹1,800.00

High / Low₹1,800 / ₹1,102

P/E26.0

P/B2.63

Book value₹684.7

ROE10.1%

ROCE13.1%

Debt / equity0.21

Dividend yield0.22%

EPS (TTM)₹69.35

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 8 periods

	FY18	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	16,500	23,098	24,775	23,455	24,855	29,002	31,724	33,653
EBITDA	3,772	4,825	5,333	4,387	3,719	5,843	6,583	6,846
Operating margin	22.9%	20.9%	21.5%	18.7%	15.0%	20.1%	20.8%	20.3%
Interest	78	160	74	49	140	290	457	384
Depreciation	558	967	1,055	1,127	1,245	1,522	1,649	1,778
Profit before tax	3,238	3,758	7,399	3,404	2,624	4,397	5,098	5,110
Tax	818	914	2,010	726	685	1,211	1,583	1,609
Net profit	0	2,831	5,339	2,648	1,928	3,173	3,486	3,505
EPS ₹	41.36	48.32	91.04	45.19	32.90	54.16	59.81	60.34
Operating cash flow	—	—	—	5,016	2,387	2,435	3,925	5,526
Capex	—	—	—	2,705	2,720	3,562	2,520	3,105
Dividend paid	—	—	—	264	440	264	0	232
Total assets	21,101	28,928	33,854	33,922	39,890	45,072	49,785	58,502
Equity	11,680	16,825	21,930	24,576	26,840	29,843	32,653	37,891

Quarterly performance

last 32 quarters · ₹ crore

showing latest 8 of 32 periods

	MAR '18	SEP '18	DEC '18	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	4,049	4,751	5,270	5,600	5,895	6,158	5,925	6,483	6,365	6,002	5,702	5,942	6,002	5,809	6,236	5,739	6,407	6,473	6,851	7,219	7,352	7,580	7,567	7,796	7,979	8,382	7,868	8,286	8,646	8,853	9,150	10,263
Operating profit	788	986	1,086	1,140	1,217	1,316	1,257	1,433	1,369	1,275	1,238	1,187	1,016	974	936	791	954	1,002	1,151	1,373	1,601	1,673	1,620	1,566	1,578	1,792	1,603	1,678	1,773	1,753	1,881	2,156
Operating margin	19.5%	20.8%	20.6%	20.4%	20.6%	21.4%	21.2%	22.1%	21.5%	21.2%	21.7%	20.0%	16.9%	16.8%	15.0%	13.8%	14.9%	15.5%	16.8%	19.0%	21.8%	22.1%	21.4%	20.1%	19.8%	21.4%	20.4%	20.3%	20.5%	19.8%	20.6%	21.0%
Other income	44	26	64	21	22	33	116	54	133	78	81	97	65	49	41	57	93	135	116	187	163	136	221	136	157	135	105	121	188	117	264	168
Interest	25	35	48	41	37	32	21	16	19	18	13	10	16	9	15	25	45	56	57	68	76	89	111	113	118	115	98	95	93	98	102	102
Depreciation	157	164	163	243	250	232	256	257	277	266	280	294	299	254	280	298	321	346	327	418	423	354	404	382	419	444	406	429	465	479	487	531
Profit before tax	651	787	914	864	939	1,097	1,096	1,214	4,020	1,069	1,027	979	801	598	683	525	681	736	815	1,075	1,265	1,243	1,325	1,207	1,198	1,367	1,205	1,274	1,338	1,293	1,517	1,691
Tax	122	175	205	224	233	229	304	387	1,059	260	248	271	189	17	159	113	189	224	242	324	322	323	406	391	354	432	383	428	429	370	483	564
Net profit	0	803	539	640	705	850	842	806	2,946	716	770	697	547	576	521	409	491	506	571	757	936	909	919	817	855	903	825	848	910	921	1,033	1,126
EPS ₹	9.02	10.44	12.15	10.92	12.04	14.50	13.32	13.75	50.29	13.67	13.14	11.89	10.32	9.84	8.88	6.99	8.38	8.64	9.74	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86	19.57
Revenue YoY	—	—	—	17.9%	11.9%	—	—	15.8%	8.0%	-2.5%	-3.8%	-8.4%	-5.7%	-3.2%	9.4%	-3.4%	6.7%	11.4%	9.9%	25.8%	14.7%	17.1%	10.5%	8.0%	8.5%	10.6%	4.0%	6.3%	8.4%	5.6%	16.3%	23.9%
Profit YoY	—	—	—	-20.3%	30.9%	—	—	26.0%	317.7%	-15.8%	-8.5%	-13.5%	-81.5%	-19.4%	-32.4%	-41.3%	-10.1%	-12.2%	9.6%	84.9%	90.6%	79.5%	61.1%	8.0%	-8.7%	-0.6%	-10.3%	3.8%	6.5%	2.0%	25.2%	32.7%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Aurobindo Pharma Ltd. reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

	FY09†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	2,792	4,281	5,425	7,111	8,095	9,166	9,741
Operating profit	516	449	893	1,919	2,206	2,449	2,374
Operating margin	18.5%	10.5%	16.5%	27.0%	27.3%	26.7%	24.4%
Other income	11	13	15	33	42	39	66
Interest	56	87	115	67	63	65	45
Depreciation	82	143	171	186	245	263	286
Profit before tax	161	-138	563	1,519	1,940	2,140	2,179
Tax	28	-95	67	347	424	520	472
Net profit	132	-43	496	1,172	1,516	1,620	1,707

Quarters

showing latest 8 of 40 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	JUN '10†	SEP '10†	DEC '10†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	612	511	632	647	636	722	787	763	826	811	868	1,050	1,157	1,030	958	1,202	1,092	1,130	1,391	1,431	1,473	1,612	1,598	1,898	2,003	1,951	2,008	2,098	2,038	2,220	2,176	2,365	2,406	2,390	2,410	2,521	2,420	2,188	3,074	2,686
Operating profit	108	55	101	120	103	134	158	169	207	211	171	267	332	170	105	69	104	185	237	218	253	368	360	580	611	588	554	563	500	599	551	690	609	566	593	634	580	470	1,039	664
Operating margin	17.6%	10.8%	15.9%	18.5%	16.2%	18.6%	20.1%	22.2%	25.0%	26.0%	19.8%	25.4%	28.7%	16.5%	11.0%	5.8%	9.5%	16.4%	17.1%	15.2%	17.2%	22.8%	22.5%	30.5%	30.5%	30.1%	27.6%	26.9%	24.6%	27.0%	25.3%	29.2%	25.3%	23.7%	24.6%	25.2%	24.0%	21.5%	33.8%	24.7%
Other income	38	39	9	7	1	3	1	1	11	2	1	3	1	2	2	2	8	1	6	1	7	3	2	13	15	6	19	12	6	25	3	2	10	10	3	2	51	30	29	34
Interest	4	3	4	7	10	18	22	18	13	10	9	16	10	12	18	25	32	30	30	28	26	21	20	17	9	7	14	26	16	15	17	17	16	14	12	10	9	10	12	13
Depreciation	19	19	19	20	20	21	21	22	24	24	27	31	35	34	34	36	38	41	42	42	46	46	47	47	46	63	60	60	63	63	66	67	67	70	71	71	73	83	90	90
Profit before tax	122	71	86	44	-21	49	90	159	186	201	91	286	291	-191	-95	10	137	-78	296	148	197	165	217	549	589	523	500	490	428	541	447	613	539	503	545	582	549	407	966	595
Tax	22	16	10	4	17	8	-1	33	57	53	28	72	107	-89	-53	-3	49	-28	58	4	34	21	38	130	158	130	108	96	91	134	107	147	132	112	125	141	93	99	214	150
Net profit	101	55	76	40	-38	41	90	126	128	148	63	214	184	-102	-42	13	88	-50	238	144	164	144	180	418	431	393	392	394	337	406	340	466	408	391	419	441	455	307	753	444
EPS ₹	18.80	10.28	14.15	7.42	-7.16	7.57	16.81	23.45	23.86	27.53	11.28	37.09	31.57	-3.49	-1.44	0.44	3.02	-1.71	8.17	4.96	5.62	4.93	6.17	14.36	14.78	13.50	13.44	13.52	11.55	13.91	5.82	7.97	6.97	6.68	7.16	7.53	7.78	5.25	12.85	7.58
Revenue YoY	—	—	—	—	3.9%	41.4%	24.4%	17.9%	30.0%	12.3%	13.7%	27.1%	42.6%	18.7%	-8.8%	3.9%	—	9.6%	45.3%	19.1%	34.9%	42.7%	14.9%	32.6%	36.0%	21.0%	25.6%	10.5%	1.8%	13.8%	8.4%	12.7%	18.0%	7.7%	10.8%	6.6%	0.6%	-8.4%	27.5%	6.5%
Profit YoY	—	—	—	—	-138.1%	-26.3%	18.8%	216.3%	—	264.1%	-49.8%	66.8%	24.0%	-260.4%	-119.6%	-93.0%	—	—	—	1015.9%	86.0%	—	-24.5%	189.8%	163.3%	173.9%	118.0%	-5.7%	-21.7%	3.2%	-13.2%	18.1%	21.0%	-3.7%	23.3%	-5.3%	11.7%	-21.4%	79.6%	0.7%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 26 periods

	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	18.0%	19.0%	32.4%	24.2%	23.9%	23.4%	12.4%	10.5%	9.5%	8.0%	7.8%	7.2%	7.4%	8.2%	9.8%	10.6%	11.8%	11.6%	11.3%	10.7%	10.4%	9.8%	10.0%	9.2%	9.8%	10.1%
ROCE	18.5%	20.0%	33.8%	27.8%	27.5%	26.6%	14.6%	12.8%	11.5%	9.0%	8.7%	8.7%	9.3%	10.3%	12.0%	13.0%	14.5%	13.9%	13.9%	13.7%	13.4%	12.9%	13.1%	12.1%	12.8%	13.1%
Net margin	12.9%	13.1%	21.8%	21.4%	21.3%	21.4%	11.5%	11.0%	9.8%	8.6%	8.3%	7.8%	7.8%	8.6%	9.9%	10.9%	11.8%	11.8%	11.3%	11.0%	10.6%	10.6%	10.5%	10.4%	10.6%	10.8%
EBITDA margin	20.9%	21.4%	21.6%	21.5%	21.6%	21.1%	19.9%	18.8%	17.1%	15.6%	15.1%	14.8%	15.3%	16.6%	18.4%	20.0%	21.1%	21.3%	20.8%	20.7%	20.4%	20.5%	20.6%	20.2%	20.3%	20.5%
Debt / equity	0.32	0.32	0.32	0.23	0.23	0.23	0.23	0.10	0.10	0.16	0.16	0.18	0.18	0.22	0.22	0.21	0.21	0.26	0.26	0.24	0.24	0.21	0.21	0.20	0.20	0.21
Interest coverage	31.51	42.10	85.30	100.33	111.55	117.28	68.22	70.98	61.73	40.94	27.42	19.68	16.11	15.68	16.20	16.18	15.26	13.97	12.52	12.15	12.21	12.83	13.94	14.31	14.98	15.79
Asset turnover	0.82	0.85	0.86	0.73	0.73	0.71	0.70	0.69	0.71	0.64	0.65	0.62	0.64	0.61	0.64	0.64	0.66	0.63	0.64	0.64	0.64	0.62	0.63	0.58	0.60	0.60

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 18 periods

	MAR '14‡	MAR '15‡	MAR '16‡	MAR '17‡	MAR '18‡	MAR '19‡	MAR '20‡	MAR '21‡	MAR '22‡	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	29	29	59	59	59	59	59	59	59	59	59	59	59	58	58	58	58	58
Other equity / reserves	3,695	5,127	6,939	9,313	11,622	13,832	16,766	21,871	24,517	25,469	26,781	28,130	29,784	30,820	32,595	34,983	37,833	39,342
Total equity	3,724	5,156	6,997	9,372	11,680	13,891	16,825	21,930	24,576	25,528	26,840	28,189	29,843	30,878	32,653	35,041	37,891	39,400
Borrowings	3,634	3,864	4,076	3,084	4,483	6,753	5,422	4,972	2,373	4,021	4,862	6,245	6,315	8,091	7,942	7,479	7,676	8,234
Current liabilities	4,220	6,136	7,476	6,606	8,666	12,021	11,385	10,665	8,156	10,450	11,494	13,012	12,199	14,341	14,682	15,501	18,039	19,667
Non-current liabilities	1,494	1,596	1,107	270	753	541	718	1,260	1,192	1,177	1,544	2,717	3,022	2,869	2,456	2,011	2,580	2,689
Total assets	9,490	12,914	15,699	16,249	21,101	26,454	28,928	33,854	33,922	37,167	39,890	43,924	45,072	48,094	49,785	52,546	58,502	61,754
Property, plant & equipment	295	404	995	4,083	4,737	5,694	6,495	6,473	7,220	7,809	7,995	7,870	11,546	11,428	12,189	13,281	14,330	15,292
Capital work-in-progress	—	—	—	1,237	1,400	1,342	1,622	2,429	2,938	3,666	4,496	5,798	2,739	3,497	3,266	3,039	3,009	3,487
Investments	20	20	0	246	312	360	555	591	997	1,543	543	435	372	325	252	268	1,051	354
Inventories	2,368	3,611	4,088	4,331	5,858	7,246	7,700	9,027	7,554	7,891	8,511	9,282	9,808	10,432	10,544	11,192	12,053	13,124
Receivables	2,637	3,539	4,172	2,765	3,080	3,415	4,315	3,503	4,012	3,656	4,466	4,640	4,817	5,562	5,854	5,891	7,094	7,544
Cash & equivalents	179	469	834	489	1,214	1,884	2,764	5,373	4,163	3,772	4,396	4,132	3,393	3,904	5,569	5,402	7,191	6,232

Cash flow

annual · ₹ crore · line = free cash flow

showing latest 5 of 13 periods

	FY14‡	FY15‡	FY16‡	FY17‡	FY18‡	FY19‡	FY20‡	FY21‡	FY22	FY23	FY24	FY25	FY26
Cash from operations	646	1,237	1,760	3,279	1,955	1,651	4,381	3,329	5,016	2,387	2,435	3,925	5,526
Cash from investing	-819	-1,398	-1,380	-1,787	-1,927	-2,903	-1,568	599	-3,215	-3,978	-4,256	-1,875	-3,458
Cash from financing	118	93	-20	-1,915	864	1,919	-1,947	-1,365	-2,969	1,814	800	120	-1,269
Capex	390	768	1,568	1,694	1,530	133	1,431	1,874	2,705	2,720	3,562	2,520	3,105
Free cash flow	256	469	191	1,584	425	1,518	2,950	1,455	2,312	-334	-1,127	1,405	2,422
Dividends paid	—	—	—	114	219	146	176	234	264	440	264	0	232

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹15,292 cr25%

CWIP

₹3,487 cr6%

Investments

₹354 cr1%

Inventories

₹13,124 cr21%

Receivables

₹7,544 cr12%

Cash & equivalents

₹6,232 cr10%

Other assets

₹15,723 cr25%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%

StoxGud checklist: Bullish setup · 9/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+7.0%

6 months+21.7%

1 year+61.9%

3Y CAGR+27.2%

5Y CAGR+21.8%

10Y CAGR+8.9%

50-day avg₹1,674.38

200-day avg₹1,471.08

RSI (14)67

Long-term financials (FY12–FY16)

from published annual reports

Year	Revenue	Profit before tax	Net profit
FY16	₹13,896 Cr	₹2,722 Cr	₹1,978 Cr
FY15	₹12,121 Cr	₹2,168 Cr	₹1,571 Cr
FY14	₹8,100 Cr	₹1,533 Cr	₹1,173 Cr
FY13	₹5,855 Cr	₹374 Cr	₹294 Cr
FY12	₹4,627 Cr	₹108 Cr	₹-124 Cr

Years before FY17 follow the older Indian GAAP standard, so they are not exactly comparable with recent years.

Compare Aurobindo Pharma Ltd. with

Dr. Reddy's Laboratories vs Aurobindo Pharma Cipla vs Aurobindo Pharma Mankind Pharma vs Aurobindo Pharma Aurobindo Pharma vs Lupin Aurobindo Pharma vs Max Healthcare Institute

FAQs

What is the share price of Aurobindo Pharma Ltd.?

Aurobindo Pharma Ltd. (AUROPHARMA) closed at ₹1,800.00 on NSE on 06 Nov 2026.

What is the market cap of Aurobindo Pharma Ltd.?

₹1,03,572 crore at the latest close.

What is the P/E ratio of Aurobindo Pharma Ltd.?

26.0, on trailing-twelve-month earnings from its filings.

How fast is Aurobindo Pharma Ltd. growing?

Aurobindo Pharma Ltd.: revenue has compounded at 10.6% a year over three years; net profit at 22.1% a year. Latest-quarter revenue is up 23.9% year on year, profit up 32.7%.

How profitable is Aurobindo Pharma Ltd.?

On a trailing-twelve-month basis return on equity is 10.1%, return on capital employed 13.1%, operating margin 20.5%, net margin 10.8%.

How much debt does Aurobindo Pharma Ltd. have?

Aurobindo Pharma Ltd. is lightly geared: debt to equity is 0.21 with borrowings of ₹8,234 cr against cash of ₹6,232 cr (balance sheet of 2026-09-30). Operating profit covers interest 15.8 times.

Financials parsed from Aurobindo Pharma Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Mar '14. * = derived (full year or half year minus earlier quarters). ‡ = balance sheet / cash flow read from the company's published annual report (same basis), for years before the NSE filings carry them; each one checked to add up. Information only, not investment advice.